Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Other financing activities: 2016-2024

Historic Other financing activities for Whitehawk Therapeutics (WHWK) over the last 8 years, with Dec 2024 value amounting to $16,000.

  • Whitehawk Therapeutics' Other financing activities rose 11371.43% to $803,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $5.6 million, marking a year-over-year increase of 4299.22%. This contributed to the annual value of $16,000 for FY2024, which is 90.00% down from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Other financing activities of $16,000 as of FY2024, which was down 90.00% from $160,000 recorded in FY2023.
  • In the past 5 years, Whitehawk Therapeutics' Other financing activities ranged from a high of $9.6 million in FY2021 and a low of $16,000 during FY2024.
  • Its 3-year average for Other financing activities is $171,000, with a median of $160,000 in 2023.
  • In the last 5 years, Whitehawk Therapeutics' Other financing activities surged by 2,287.57% in 2021 and then plummeted by 96.50% in 2022.
  • Whitehawk Therapeutics' Other financing activities (Yearly) stood at $402,795 in 2020, then skyrocketed by 2,287.57% to $9.6 million in 2021, then slumped by 96.50% to $337,000 in 2022, then tumbled by 52.52% to $160,000 in 2023, then plummeted by 90.00% to $16,000 in 2024.